Abstract 1673P
Background
Imposter Syndrome (IS) is defined as “the inability to internalize achievement and a tendency to attribute success to external factors such as luck, error, or personal connections. It has been associated with psychological distress, emotional suffering, and significant mental health issues. It has also been associated with Burnout (BO), characterized by the emotional exhaustion of individuals in their careers, depersonalization toward other individuals, and a decrease in the sense of personal accomplishments. The study aimed to evaluate the factors associated with IS and its association with BO in medical oncologists (MOs).
Methods
A cross-sectional study was conducted focusing on the MOs actively working in the field. They were invited to the study via mailing list. The sociodemographic and academic data were collected. The IS scores (ISS) was tested using the Clance imposter phenomenon Scale and BO was tested by using the Maslach burnout inventory. The subscales of BO; emotional exhaustion (EE), depersonalization (DP), and personal accomplishment (PA) were analyzed. The characteristics associated with IS and BO were tested by univariate and multivariate analysis.
Results
In the study, 417 MOs with a median age of 40(29-68) were evaluated. The mean of ISS was 50.8+/-15.3, and 122(29.3%) participants had high ISS. The multivariate analysis revealed that female gender was the only factor associated with high ISS (OR: 1.85, CI95%, 1.1- 2.9, p=0.009). While there was a strong positive correlation between ISS and EE (r=0.54, p<0.001) and DP (r=0.48, p<0.001), a strong and negative correlation was found between ISS and PA score (r= -0.41, p<0.001). In the multivariate analysis; high ISS score was the only statistically significant parameter associated with a high EE score (OR:5.03, CI 95% 3.1-8.0, p<0.001), high DP scores (OR=3.4, CI 95% 1.8- 6.5, p<0.001) and low PA scores. (OR=3.73, CI 95% 1.9- 7.1, p<0.001).
Conclusions
The results of the study indicated that IS is prevalent in MOs. The MOs with IS were more emotionally exhausted and more depersonalized. In addition, they had less feeling of personal accomplishment. The IS and its consequences on MOs should be further studied and the strategies to cope with IS should be developed.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1617P - Multi-gene copy number variation risk-score for prediction of survival and therapy response outcome in treatment-naïve metastatic castrate resistant prostate cancer
Presenter: Manish Kohli
Session: Poster session 11
1618P - Clinical prognostic factors within the high volume subgroup of metastatic hormone sensitive prostate cancer (mHSPC) in ENZAMET (ANZUP 1304)
Presenter: Anis Hamid
Session: Poster session 11
1619P - Efficacy of carboplatin in patients with metastatic castration-resistant prostate cancer: Results from the biomarker-driven, randomised, outcome-adaptive ProBio trial
Presenter: Anna Kristiansen
Session: Poster session 11
1620P - Inherited variants in SRD5A genes and response to hormonal therapy in prostate cancer (SWOG S1216)
Presenter: Sue Ingles
Session: Poster session 11
Resources:
Abstract
1621P - Validation of a digital pathology-based multimodal artificial intelligence (MMAI) prostate biopsy biomarker in a prospective, real-world Swedish prostate cancer (PCa) cohort treated with radical prostatectomy
Presenter: Anders Bjartell
Session: Poster session 11
1622P - A phase II study of the first-in-class oral innate immune activator BXCL701 with pembrolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC): Long-term follow-up
Presenter: Rahul Aggarwal
Session: Poster session 11
1623P - Prognostic value of circulating tumour DNA fraction in metastatic castration-resistant prostate cancer: Insights from the ProBio trial
Presenter: Alessio Crippa
Session: Poster session 11
1624P - Total and regional changes in body composition in metastatic hormone-sensitive prostate cancer (mHSPC) patients randomized to receive androgen deprivation + enzalutamide +/- zoledronic acid: The BonEnza study
Presenter: Martina Buffoni
Session: Poster session 11
1625P - Fuzuloparib combined with abiraterone in the neoadjuvant treatment of localised high-risk prostate cancer (FAST-PC): A single-arm phase II study
Presenter: Yao Zhu
Session: Poster session 11